Artery.com's "2018 Future Healthcare 100" list was officially released, and CGeneTech was honored to be listed

Categories:Media
Author:Arterial network
Origin:Arterial network
Time of issue:2018-12-20
Views:0

(Summary description)On December 18-19, 2018, Artery.com's "2018 Future Healthcare 100" Forum was held at Renaissance Beijing Hotel. More than 2,500 domestic and international healthcare industry elites attended the event.

Artery.com's "2018 Future Healthcare 100" list was officially released, and CGeneTech was honored to be listed

(Summary description)On December 18-19, 2018, Artery.com's "2018 Future Healthcare 100" Forum was held at Renaissance Beijing Hotel. More than 2,500 domestic and international healthcare industry elites attended the event.

Categories:Media
Author:Arterial network
Origin:Arterial network
Time of issue:2018-12-20
Views:0

　　On December 18-19, 2018, Artery.com's "2018 Future Healthcare 100" Forum was held at Renaissance Beijing Hotel. More than 2,500 domestic and international healthcare industry elites attended the event.

　 On the 18th, Artery.com released the four main lists of "2018 Future Healthcare 100": "China Healthcare Top 100", "China Medicine Top 100", "China Health Top 30" and "Overseas Top 100". The four main lists were "China Health List Top 30" and "Overseas List Top 100". Centurion is fortunate to occupy one of the top 100 China Medical List.

　　In addition, Artery.com has added sub-lists (TOP5) in niche areas (rehabilitation robotics, DTP pharmacy, third-party medical services and 12 other areas), as well as "China Top Industrial Park TOP10" and "China Top Industrial New City TOP10" from 2018. ".

　　In this era of exploring the future of healthcare, we are looking forward to new technological breakthroughs and innovations, model explorations and improvements that will bring more excitement to the future of human health.

　　As an observer and recorder of the industry, we hope to see social change, economic ups and downs and consumer evolution from a Chinese and global perspective, and to discover the direction of change in the health care industry from a broader perspective. "The Future Healthcare 100 aims to select innovative Chinese healthcare companies that truly represent the future of healthcare, discover the core strengths of China's future healthcare industry, and promote the process of innovation and change in the healthcare industry.

　　In 2018, the "Future Healthcare 100" list has gone through three stages of production: preliminary selection, review and validation, to explore the most promising companies in various healthcare segments. The list provides a benchmark for innovative companies, a guide for investment institutions and value for audiences.

　　The list of companies on the Future Healthcare 100 China 2018 is as follows.

The list of companies on the Future of Healthcare 100 China Medicine list for 2018 is as follows.

The list of companies on the Future of Health 100 China Health List 2018 is as follows.

The list of overseas companies in the Future of Healthcare 100 2018 is as follows.

　　 The 2018 Future Healthcare Industry Report released by Arteries.com - Eggshell Research Institute points out that 2018 was a year of change in the healthcare sector, and China has made a series of achievements in the reform of the sector. The capacity of medical services has been strengthened, the capacity of public health services has been improved, the management of medical institutions has been gradually standardised, the coverage of medical insurance services has been further expanded, the support of regulators for innovative drugs has been stepped up, and medical-related innovative technologies have emerged ......
　　These factors have led to the emergence of a number of high-profile companies in various healthcare innovation segments, from traditional companies with a strong commitment to innovation to start-ups that are making the most noise in the healthcare innovation process.
　　The "Future Healthcare 100" 2018 annual awards are voted by a panel of judges selected from industry experts, investors and policy researchers, and selected by the Artery Network Content Center, the Eggshell Institute and industry judges, to present the "Future Healthcare 100 The final results include the "Future Healthcare 100" sub-list, the "City New Town" list and the "Park" list.
　　The sub-lists include "Rehabilitation Robot", "DTP Pharmacy", "Third Party Medical Services", "Internet of Medical Things", "Pediatric Clinics ", "Paediatric Clinics", "Doctor Groups", "Digital Chinese Medicine", "Digital Equipment for Pharmacies ", "Insurance Payments", "Consumer Genetics", "Gene Editing", "Microbiology " twelve sub-lists, listed below.

2018 Future Healthcare 100 - China List The Industrial Park List/Industrial New City List is as follows.

Source: arterial.com

Previous: Spotlight on Science and Technology Board - Suzhou Industrial Park Science and Technology Enterprises Mapping: Some Charge, Some Wait and See

Next: Jiangsu Science and Technology Weekly People - Yu Qiang: No "old" drugs, no coincidences, down-to-earth new drugs for diabetes

Previous: Spotlight on Science and Technology Board - Suzhou Industrial Park Science and Technology Enterprises Mapping: Some Charge, Some Wait and See

Next: Jiangsu Science and Technology Weekly People - Yu Qiang: No "old" drugs, no coincidences, down-to-earth new drugs for diabetes

New generation of highly selective DPP-4 inhibitors international diabetes expert Professor Ji Linong interprets Shengglitin Phase III clinical data

2023-05-31

The world's first SGLT-2/DPP-4 dual target inhibitor with complementary advantages has been approved for clinical use

Recently, Shengshi Taike's Class 1 innovative drug SGLT-2/DPP-4 dual target inhibitor CGT-2201 has been granted implicit permission for clinical trials by the National Drug Administration. CGT-2201, which targets SGLT-2 and DPP-4, two important targets related to glucose metabolism, can be better used for the treatment of diabetes and its derivatives, including diabetes nephropathy and non-alcoholic fatty liver disease. In 2021, the number of diabetes patients in China will reach 141 million, ranking first in the world. Among the numerous patients with diabetes in China, 20-40% may suffer from complications of diabetes nephropathy. Among the existing hypoglycemic drugs, only sodium glucose cotransporter 2 (SGLT-2) inhibitor has significant renal protection effect in clinical verification, but its inherent reproductive and urinary system infection risks limit its use. Based on SGLT-2 inhibitors and combined with the characteristics of dipeptidyl peptidase 4 (DPP-4) inhibitors, we design and develop a drug that can improve blood sugar, reduce side effects of urinary and reproductive system infections, is not limited by renal function, and has kidney benefits. It is expected to fill the market gap and meet the needs of patients. Based on this market background and target characteristics, Shengshi Taike utilizes its own small molecule chimera drug technology platform to develop multi head multifunctional new drug products with synergistic mechanisms, with CGT-2201 being one of its representative works. It fuses the respective mechanism characteristics of SGLT-2 and DPP-4. On the basis of inhibiting the activity of SGLT-2 to reduce the reabsorption of glucose in the kidney, it also slows down the inactivation of DPP-4 on GLP-1, playing a dual role mechanism to play a superposition effect; While achieving considerable hypoglycemic effect, it can reduce the side effects of existing SGLT-2 drug urinary system infection; At the same time, without kidney excretion, it can reduce the burden of the kidney and reduce the contraindication of diabetes patients with renal insufficiency. Therefore, this drug will have the advantage of better controlling blood sugar and protecting patient kidney function. Shengshi Tyco was founded in Suzhou Industrial Park in 2010. Its core team has decades of experience in the whole life cycle of international drugs, and is committed to the R&D and industrialization of high-quality and differentiated small molecule innovative drugs. The company has built a product pipeline covering multiple disease fields such as hypoglycemic, anticancer, and autoimmune diseases with an integrated drug research and development technology platform and a diversified business perspective. In the field of hypoglycemic drugs, Shenggliptin, the core product independently developed by the company, has submitted an NDA (product launch application) to the National Drug Administration and has been accepted. The results of the Phase 3 clinical trial showed that low doses can reach the predetermined trial endpoint, while the high-dose group can also demonstrate the safety of the drug well. The therapeutic effect of "half the dose" is twice as effective, making it expected to become the best hypoglycemic drug in the class. At the same time, the company has also carried out a comprehensive layout around oral drugs and derivative diseases of various targets related to diabetes. CGT-2201, which was approved for clinical use this time, is one of its pipeline matrix members.

2023-04-20